Revolution Medicines, Inc.
About Revolution Medicines, Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $0
- Net income
- -$1.1B
- Total assets
- $2.4B
- Market cap
- $31.7B
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $1.2B
- Operating income
- -$1.2B
- Income tax
- $0
- Net income
- -$1.1B
- EPS (basic)
- $-5.95
- EPS (diluted)
- $-5.95
Balance sheet
- Total assets
- $2.4B
- Current assets
- $2.1B
- Total liabilities
- $723.2M
- Current liabilities
- $290.4M
- Shareholders’ equity
- $1.6B
Cash flow
- Operating cash flow
- -$897.7M
- Investing cash flow
- $118.1M
- Financing cash flow
- $621.5M
- Net cash flow
- -$158.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $31.7B
- EPS (diluted)
- $-5.95
- Shares outstanding
- 213.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 13, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $1.1B in FY2025.
- Trading 9% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Revolution Medicines, Inc..
Write a review
News about Revolution Medicines, Inc.
News & sentiment via Polygon.io
